What Researchers Did
Chinese researchers reviewed existing evidence on HBOT as an adjunct therapy for glioma, focusing on how it interacts with surgery, radiation, chemotherapy, and photodynamic therapy.
What They Found
HBOT may help overcome tumor hypoxia, which makes glioma cells resistant to radiation and chemotherapy. Combined treatments showed better outcomes in multiple studies. HBOT is not licensed for cancer treatment but is lower cost and well tolerated.
What This Means for Canadian Patients
For Canadians with glioma facing radiation or chemotherapy, HBOT may sensitize tumours to treatment by increasing oxygen levels in the oxygen-poor tumor core, potentially making standard therapies more effective without adding significant side effects.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This is a narrative review; included studies varied widely in design and quality, and HBOT remains unapproved specifically for cancer treatment pending rigorous clinical trial data.